January 3rd 2024
This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.
ASRS 2020: How one surgeon is integrating recent retina advances in COVID-19
August 2nd 2020S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment
ASRS 2020: PDS with ranibizumab signals paradigm shift in treatment of neovascular AMD
July 27th 2020PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.
Evaluating the change in VA, CMT after early switch of anti-VEGF drugs
July 22nd 2020The study authors hypothesized that patients poorly responding to ranibizumab may have resulted from tachyphylaxis or tolerance to the drug and regarding the nonresponders, they speculated that VEGF-A may not have been the main cause of the neovascular growth.
Intravitreal gene therapy holds promise for novel wet AMD treatment
July 17th 2020An in-office intravitreal therapy delivering a gene for aflibercept expression continues to demonstrate encouraging safety, tolerability, and efficacy in a phase 1 study of patients with neovascular age-related macular degeneration who require frequent injections to control their disease.